Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.

导出 LinkOut

翻译打印收藏纠错

作者： Jordan J,Feld ^[1] ; Ira M,Jacobson ^[2] ; Donald M,Jensen ^[3] ; Graham R,Foster ^[4] ; Stanislas,Pol ^[5] ; Edward,Tam ^[6] ; Maciej,Jablkowski ^[7] ; Hanna,Berak ^[8] ; John M,Vierling ^[9] ; Eric M,Yoshida ^[10] ; Héctor R,Perez-Gomez ^[11] ; Astrid,Scalori ^[12] ; Gregory J,Hooper ^[12] ; Jorge A,Tavel ^[13] ; Mercidita T,Navarro ^[13] ; Saba,Shahdad ^[12] ; Rohit,Kulkarni ^[13] ; Sophie,Le Pogam ^[14] ; Isabel,Nájera ^[15] ; Simon,Eng ^[13] ; Chin Yin,Lim ^[13] ; Nancy S,Shulman ^[13] ; Ellen S,Yetzer ^[13]

作者单位： Toronto Centre for Liver Disease, McLaughlin-Rotman Centre for Global Health, Toronto, ON, Canada. Electronic address: jordan.feld@uhn.ca. ^[1] Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY, USA. ^[2] Center for Liver Diseases, University of Chicago Hospitals, Chicago, IL, USA. ^[3] Queen Mary, University of London, Institute of Cellular and Molecular Sciences, London, UK. ^[4] Hôpital Cochin, Université Paris Descartes and INSERM U1610, Paris, France. ^[5] LAIR Centre, Vancouver, BC, Canada. ^[6] Medical University of Lodz, Lodz, Poland. ^[7] Hospital of Infectious Diseases, Warsaw, Poland. ^[8] Baylor College of Medicine, Houston, TX, USA. ^[9] University of British Columbia, Vancouver, BC, Canada. ^[10] Hospital Civil de Guadalajara, Instituto de Patologia Infecciosa, Universidad de Guadalajara, Guadalajara, Mexico. ^[11] Roche Products Ltd, Welwyn, UK. ^[12] Genentech, South San Francisco, CA, USA. ^[13] Hoffmann-La Roche Inc, Nutley, NJ, USA. ^[14] F. Hoffmann-La Roche Ltd, Basel, Switzerland. ^[15]

关键词 Danoprevir Genotype 1 HCV Mericitabine Non-responders Peginterferon/ribavirin Quad therapy